Swayed by lack of alternatives, ODAC votes to retain Tecentriq accelerated approval for triple-negative breast cancer
Given lack of confirmatory data, the outcome could lower confidence in accelerated approval pathway
The lack of substantially better alternative therapies, rather than compelling clinical data, seems to have prompted an FDA advisory committee to vote 7-2 Tuesday against withdrawing accelerated approval for Genentech’s Tecentriq with nab-paclitaxel to treat PD-L1-positive triple-negative breast cancer.
FDA granted accelerated approval to Tecentriq atezolizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) in March 2019 for TNBC based on data from the IMpassion130 trial. The data showed that patients who received the drug experienced a median 7.4 months of progression-free survival (PFS) compared with 4.8 months for those who received nab-paclitaxel plus placebo. ...